Abstract:Background Glycogen synthase kinase 3β (GSK3β) was originally discovered to regulate glycogen synthesis and show a relationship to tumors. However, the biological functions of GSK3β in tumor-associated macrophages (TAMs) in cancers including hepatocellular carcinoma (HCC) remain unclear. Methods The enrichment of GSK3β in tumor tissues was assessed by Gene Expression Omnibus (GEO) database. The in vitro and in vivo assays assisted in evaluating how GSK3β in TAMs affected HCC in terms of proliferation, invasion and migration. Immunofluorescence was used to assess GSK3β expression in TAMs in the anti-PD1 therapy non-responsive HCC group and the responsive group. Western blot and coimmunoprecipitation were performed to demonstrate the interaction between GSK3β and PD-L1. We carried out in vivo experiments in a C57BL/6 mouse model of HCC established through subcutaneous injection. Results GEO single-cell RNA sequencing data suggested that GSK3β was highly enriched in TAMs of HCC. According to in vitro and in vivo experiments, reducing GSK3β in TAMs inhibits the cancer cell proliferation, invasion, and migration. The immunofluorescence and immunohistochemistry results confirmed that the GSK3β is significantly upregulated in TAMs of the anti-PD1 therapy non-responsive group in comparison with the responsive group. In vitro and in vivo experiments confirmed that reduced GSK3β in TAMs are capable of enhancing the sensitivity of anti-PD1 immunotherapy for HCC by decreasing PD-L1 ubiquitination. Mass spectrometry results suggested that high expression of CD14 + GSK3β + in the peripheral blood mononuclear cell (PBMC) can predict non-responsive to anti-PD1 treatment. Moreover, escitalopram is confirmed to act as GSK3β inhibitor that can increase the sensitivity of anti-PD1 immunotherapy for HCC. Conclusions This study revealed that macrophage GSK3β deficiency can inhibit the development of HCC by inhibiting the M2 phenotype and enhance the sensitivity of anti-PD1 immunotherapy for HCC by decreasing PD-L1 ubiquitination. The expression of CD14 + GSK3β + in PBMC can noninvasively predict anti-PD1 sensitivity in HCC patients, which provides novel strategies to predict anti-PD1 sensitivity, increase anti-PD1 therapeutic effect, and bring new hope for HCC patients.

Macrophage Xct Deficiency Drives Immune Activation and Boosts Responses to Immune Checkpoint Blockade in Lung Cancer.

Macrophage-specific xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Blockade of C5a Receptor Unleashes Tumor-Associated Macrophage Antitumor Response and Enhances CXCL9-dependent CD8+ T Cell Activity

Mechanism of TCF21 Downregulation Leading to Immunosuppression of Tumor-Associated Macrophages in Non-Small Cell Lung Cancer

Upregulation of Exosome Secretion from Tumor-Associated Macrophages Plays a Key Role in the Suppression of Anti-Tumor Immunity.

ETS1 Deficiency in Macrophages Suppresses Colorectal Cancer Progression by Reducing the F4/80+TIM4+ Macrophage Population

Transcription Factor C-Maf is a Checkpoint That Programs Macrophages in Lung Cancer.

Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response

Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer

Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade

LAMC2 promotes the proliferation of cancer cells and induce infiltration of macrophages in non-small cell lung cancer

LAMTOR1 Phosphorylation of Exo70 Facilitates Tumor-Associated Macrophage Polarization to Restrain CD8+ T Cell Function in HCC

Breast cancer cells promote CD169<SUP>+</SUP> macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages

Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma.

Single-cell RNA sequencing reveals recruitment of the M2-like CCL8 macrophages in Lewis lung carcinoma-bearing mice following hypofractionated radiotherapy

C1q + tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion

CXCR6+ tumor-associated macrophages identify immunoevasive colon cancer patients with poor prognosis but favorable response to adjuvant chemotherapy

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer